Pharmakogenetik in der Kardiologie

Samani NJ, Erdmann J, Hall AS et al. (2007) Genomewide association analysis of coronary artery disease. N Engl J Med (in press) Eichelbaum M, Spannbrucker N, Steincke B et al. (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183–187 Mahgoub A, Idle JR, Dring LG et al. (1977) Polymorphic hydroxylation of Debrisoquine in man. Lancet 2: 584–586 Inglis SC, Herbert MK, Davies BJ et al. (2007) Effect of CYP2D6 metabolizer status on the disposition of the (+) and (–) enantiomers of perhexiline in patients with myocardial ischaemia. Pharmacogenet Genomics 17: 305–312 Darbar D, Roden DM (2006) Pharmacogenetics of antiarrhythmic therapy. Expert Opin Pharmacother 7: 1583–1590 Lee JT, Kroemer HK, Silberstein DJ et al. (1990) The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med 322: 1764–1768 Kannankeril PJ, Roden DM (2007) Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol 22: 39–43 Schmidt GA, Hoehns JD, Purcell JL et al. (2007) Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med 20: 411–416 Rau T, Heide R, Bergmann K et al. (2002) Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 12: 465–472 Wuttke H, Rau T, Heide R et al. (2002) Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 72: 429–437 Clark DW, Morgan AK, Waal-Manning H (1984) Adverse effects from metoprolol are not generally associated with oxidation status. Br J Clin Pharmacol 18: 965–967 Zineh I, Beitelshees AL, Gaedigk A et al. (2004) Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 76: 536–544 Fux R, Morike K, Prohmer AM et al. (2005) Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 78: 378–387 Giessmann T, Modess C, Hecker U et al. (2004) CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther 75: 213–222 Hein L (2001) Physiological significance of beta-adrenergic receptor polymorphisms: in-vivo or in-vitro veritas? Pharmacogenetics 11: 187–189 Mason DA, Moore JD, Green SA et al. (1999) A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 274: 12670–12674 Rathz DA, Brown KM, Kramer LA et al. (2002) Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 39: 155–160 Leineweber K, Buscher R, Bruck H et al. (2004) Beta-adrenoceptor polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 369: 1–22 Brodde OE (2007) Beta-adrenoceptor blocker treatment and the cardiac beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure. Naunyn Schmiedebergs Arch Pharmacol 374: 361–372 Wagoner LE, Craft LL, Zengel P et al. (2002) Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure. Am Heart J 144: 840–846 Buscher R, Belger H, Eilmes KJ et al. (2001) In-vivo studies do not support a major functional role for the Gly389Arg beta 1-adrenoceptor polymorphism in humans. Pharmacogenetics 11: 199–205 Liu J, Liu ZQ, Tan ZR et al. (2003) Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 74: 372–379 White HL, De Boer RA, Maqbool A et al. (2003) An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 5: 463–468 Beitelshees AL, Zineh I, Yarandi HN et al. (2006) Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics. Pharmacogenomics J 6: 174–178 Brodde OE, Leineweber K (2005) Beta2-adrenoceptor gene polymorphisms.Pharmacogenet Genomics 15:267–275. Wagoner LE, Craft LL, Singh B et al. 2000; Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res 86: 834–840 Lanfear DE, Jones PG, Marsh S et al. (2005) Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA 294: 1526–1533 Bruck H, Schwerdtfeger T, Toliat M et al. (2007) Presynaptic alpha-2C adrenoceptor-mediated control of noradrenaline release in humans: genotype- or age-dependent? Clin Pharmacol Ther (in press) Hallberg P, Karlsson J, Kurland L et al. (2002) The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens 20: 2089–2093 Lee CR, Pieper JA, Hinderliter AL et al. (2003) Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. Pharmacotherapy 23: 720–725 Sekino K, Kubota T, Okada Y et al. (2003) Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 59: 589–592 The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525–533 Ahmed A, Pitt B, Rahimtoola SH et al. (2007) Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol (in press) Zhang Y, Benet LZ (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40: 159–168 Hoffmeyer S, Burk O, von Richter O et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97: 3473–3478 Cascorbi I (2006) Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112: 457–473 Williams D, Feely J (2002) Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 41: 343–370 Kirchheiner J, Kudlicz D, Meisel C et al. (2003) Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (–)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 74: 186–194 Mwinyi J, Johne A, Bauer S et al. (2004) Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 75: 415–421 Niemi M, Schaeffeler E, Lang T et al. (2004) High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14: 429–440 Maitland-van der Zee AH, Boerwinkle E (2005) Pharmacogenetics of response to statins: where do we stand? Curr Atheroscler Rep 7: 204–208 Mangravite LM, Thorn CF, Krauss RM (2006) Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J 6: 360–374 Aithal GP, Day CP, Kesteven PJ et al. (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353: 717–719 Sconce EA, Khan TI, Wynne HA et al. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106: 2329–2333 Wadelius M, Pirmohamed M (2007) Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 7: 99–111 Carlquist JF, Horne BD, Muhlestein JB et al. (2006) Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 22: 191–197 Muszkat M, Blotnik S, Elami A et al. (2007) Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions. Clin Ther 29: 427–437 Caraco Y, Blotnick S, Muszkat M (2007) CYP2C9 Genotype-guided Warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther (in press) Ufer M (2005) Effects of CYP2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther 77: 335–336 Penning-van Beest F, Erkens J, Petersen KU et al. (2005) Main comedications associated with major bleeding during anticoagulant therapy with coumarins. Eur J Clin Pharmacol 61: 439–444 Hulot JS, Bura A, Villard E et al. (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108: 2244–2247 Wojnowski L, Kulle B, Schirmer M et al. (2005) NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112: 3754–3762 Altman RB (2007) PharmGKB: a logical home for knowledge relating genotype to drug response phenotype. Nat Genet 39: 426 Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487–491 Small KM, Wagoner LE, Levin AM et al. (2002) Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347: 1135–1142 Liggett SB (2000) Pharmacogenetics of beta-1- and beta-2-adrenergic receptors. Pharmacology 61: 167–173 Klein TE, Chang JT, Cho MK et al. (2001) Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J 1: 167–170